About
Technology
Issues
FAQ
Search
filter by year
2024 (6)
2023 (255)
2022 (765)
2021 (973)
2020 (920)
2010-2019 (6,529)
2000-2009 (3,528)
1990-1999 (2,092)
1980-1989 (1,202)
1970-1979 (381)
1960-1969 (137)
1950-1959 (27)
1900-1950 (18)
Similar Keywords
peripheral neuropathy (17,119)
1-20 of (17,119 documents found)
2013
4.4K
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
New England Journal of Medicine
(
13.9
★★★
), 369, 1691-1703.
Cite
Citations
Matthew Li (80, 6.9K)
2014
3.5K
Diagnosis and Classification of Diabetes Mellitus
Diabetes Care
(
4.3
★★★
), 37, S81-S90.
Cite
Citations
Matthew Li (80, 6.9K)
2010
4.4K
Diagnosis and Classification of Diabetes Mellitus
Diabetes Care
(
4.3
★★★
), 33, S62-S69.
Cite
Citations
Matthew Li (80, 6.9K)
2017
731
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
New England Journal of Medicine
(
13.9
★★★
), 376, 1311-1320.
Cite
Citations
Matthew Li (80, 6.9K)
2016
765
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
New England Journal of Medicine
(
13.9
★★★
), 374, 1621-1634.
Cite
Citations
Matthew Li (80, 6.9K)
2020
406
First-Line Lorlatinib or Crizotinib in Advanced
ALK
-Positive Lung Cancer
New England Journal of Medicine
(
13.9
★★★
), 383, 2018-2029.
Cite
Citations
Matthew Li (80, 6.9K)
2011
2.5K
Diagnosis and Classification of Diabetes Mellitus
Diabetes Care
(
4.3
★★★
), 34, S62-S69.
Cite
Citations
Matthew Li (80, 6.9K)
2010
1.1K
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
New England Journal of Medicine
(
13.9
★★★
), 363, 1812-1821.
Cite
Citations
Matthew Li (80, 6.9K)
2003
2.3K
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
New England Journal of Medicine
(
13.9
★★★
), 348, 2609-2617.
Cite
Citations
Matthew Li (80, 6.9K)
2021
682
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Lancet, The
(
6.3
★★★
), 398, 27-40.
Cite
Citations
Matthew Li (80, 6.9K)
2020
377
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
New England Journal of Medicine
(
13.9
★★★
), 382, 893-902.
Cite
Citations
Matthew Li (80, 6.9K)
2018
465
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
New England Journal of Medicine
(
13.9
★★★
), 378, 331-344.
Cite
Citations
Matthew Li (80, 6.9K)
2007
1.2K
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine
(
13.9
★★★
), 357, 2123-2132.
Cite
Citations
Matthew Li (80, 6.9K)
2013
1.5K
Diagnosis and Classification of Diabetes Mellitus
Diabetes Care
(
4.3
★★★
), 36, S67-S74.
Cite
Citations
Matthew Li (80, 6.9K)
2020
635
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet Oncology, The
(
5.1
★★★
), 21, 44-59.
Cite
Citations
Matthew Li (80, 6.9K)
2013
1.1K
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Lancet, The
(
6.3
★★★
), 381, 1203-1210.
Cite
Citations
Matthew Li (80, 6.9K)
2019
977
Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable
Medicine and Science in Sports and Exercise
(
0.2
★★★
), 51, 2375-2390.
Cite
Citations
Matthew Li (80, 6.9K)
2012
1.3K
Diagnosis and Classification of Diabetes Mellitus
Diabetes Care
(
4.3
★★★
), 35, S64-S71.
Cite
Citations
Matthew Li (80, 6.9K)
2010
1.0K
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
Lancet, The
(
6.3
★★★
), 376, 419-430.
Cite
Citations
Matthew Li (80, 6.9K)
2009
1.4K
Diagnosis and Classification of Diabetes Mellitus
Diabetes Care
(
4.3
★★★
), 32, S62-S67.
Cite
Citations
Matthew Li (80, 6.9K)
1
2
3
site/software ©
exaly
; All materials licenced under
CC by-SA
.